![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
June 11, 2024
Dustin A. “Dusty” Deming, MD, is the young investigator of the year for the ECOG-ACRIN Cancer Research Group
June 11, 2024
The group is recognizing Dr. Wakelee for her sustained commitment to developing women’s careers in cancer medicine and advancing women investigators in ECOG-ACRIN
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
June 11, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 13, 2024
This randomized phase 3 trial is comparing treatment with chemotherapy alone or with immunotherapy
May 1, 2024
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
May 1, 2024
Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the 2024 ASCO Annual Meeting
May 1, 2024
Summaries of recently published ECOG-ACRIN research results
May 1, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 11, 2024
This phase 2 imaging biomarker trial is evaluating whether novel biomarkers can accurately identify which patients will have better vs. worse survival outcomes early in their disease course
April 9, 2024
This phase 2/3 trial is comparing the safety and efficacy of treatment with nivolumab, ipilimumab, and sargramostim to treatment with nivolumab and ipilimumab alone